Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review.

Pediatr Blood CancerJul 25, 2026 (epub)
Clinical ResearchOncology (Medical)

Raya Dean, Lara V Graham, Christina Putnam et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the role of natural killer (NK) cells in pediatric soft tissue sarcomas (pSTS), focusing on their presence, activity, and therapeutic potential. The review found that various pSTS subtypes, particularly rhabdomyosarcoma (RMS), are susceptible to NK cell-mediated lysis, with ongoing clinical trials exploring NK cell therapies.

Key findings

  • Preclinical studies show NK cells can mediate lysis in several pSTS subtypes, including RMS.
  • Cytokine activation and sensitizing agents enhance NK cell-mediated killing of pSTS cells in vitro.
  • CAR-NK cells exhibit potent cytotoxicity against RMS in both in vitro and in vivo models.
  • Ongoing clinical trials are assessing the adoptive transfer of NK cells in pSTS patients.

Why it matters

Understanding the role of NK cells in pSTS could lead to novel therapeutic strategies, particularly for aggressive subtypes like RMS. This may improve treatment outcomes for affected pediatric patients.

Source

PubMed · PMID 42500831

Published in Pediatr Blood Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.